← FDA Drug Approvals (Drugs@FDA)

SUCRALFATE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: VISTAPHARM LLC · Approved 2022-03-15

Drug application

FDA Application #

ANDA211884

Application type

Abbreviated New Drug Application (Generic)

Brand name

SUCRALFATE

Generic name

SUCRALFATE ORAL SUSPENSION

Active ingredients

SUCRALFATE

Dosage form

SUSPENSION

Route

ORAL

Marketing status

Prescription

Sponsor

VISTAPHARM LLC

Manufacturer

Major Pharmaceuticals

First approval

2022-03-15

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown